About this trial
Colorectal and pancreatobiliary cancers are the most common digestive cancers. Their incidence has particularly increased over the last few decades, leading to suspicion that environmental factors are involved. In addition, strategies for the therapeutic management of these cancers are evolving in the context of the development of immunotherapies.
Tumor microenvironment is a potential source of new diagnostic, prognostic and predictive markers and new therapeutic targets. The links between tumor microenvironment and modulation of the immune system in colorectal and pancreatobiliary cancers are poorly understood. Molecular classifications have been proposed for these cancers, but their link with immunity and response to treatment remains to be explored.
Objective : explore links between molecular subtypes, tumor microenvironment, host (immune system, pre-metastatic niche, intestinal microbiota, metabolism), and survival (prognostic value), response (predictive value) and tolerance (toxicities) to treatments in digestive cancers, in particular colorectal and pancreatobiliary cancers.
Method: Retrospective and prospective monocentric cohort study
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Colorectal or pancreatic adenocarcinoma or biliary tract adenocarcinoma
Cytologically or histologically proven adenocarcinoma, regardless of stage and treatment
Age ≥ 18 years old
Diagnosed from 2015 onwards
Disqualifiers
Patient under guardianship, curatorship or safeguarding of justice
Pregnant or breastfeeding woman
Any medical, psychological or social situation that could prevent compliance with the protocol according to the investigator's assessment.
Refusal to participate in the study
Trial design
Single group
Treatments tested in this trial
Tumor samples
Biological/Vaccinefor each patient: liver sampling, blood samples ( serum, plasma, PBMC, whole blood), per-endoscopic bile sampling, stool samples, and materials derived from fresh tumors
Treatment groups
Trial outcomes
Primary outcomes
overall survival
Overall survival (OS): vital status (alive/deceased)
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: